Division of Nephrology, Department of Medicine McGill University Health Centre Montreal Quebec Canada.
Mike and Valeria Centre for Cardiovascular Prevention, Department of Medicine McGill University Health Centre Montreal Quebec Canada.
J Am Heart Assoc. 2022 Oct 18;11(20):e025858. doi: 10.1161/JAHA.122.025858. Epub 2022 Oct 10.
In 2019, the European Society of Cardiology/European Atherosclerosis Society stated that apolipoprotein B (apoB) was a more accurate marker of cardiovascular risk than low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol. Since then, the evidence has continued to mount in favor of apoB. This review explicates the physiological mechanisms responsible for the superiority of apoB as a marker of the cardiovascular risk attributable to the atherogenic apoB lipoprotein particles chylomicron remnants, very low-density lipoprotein, and low-density lipoprotein particles. First, the nature and relative numbers of these different apoB particles will be outlined. This will make clear why low-density lipoprotein particles are almost always the major determinants of cardiovascular risk and why the concentrations of triglycerides and LDL-C may obscure this relation. Next, the mechanisms that govern the number of very low-density lipoprotein and low-density lipoprotein particles will be outlined because, except for dysbetalipoproteinemia, the total number of apoB particles determines cardiovascular risk, Then, the mechanisms that govern the cholesterol mass within very low-density lipoprotein and low-density lipoprotein particles will be reviewed because these are responsible for the discordance between the mass of cholesterol within apoB particles, measured either as LDL-C or non-high-density lipoprotein cholesterol, and the number of apoB particles measured as apoB, which creates the superior predictive power of apoB over LDL-C and non-high-density lipoprotein cholesterol. Finally, the major apoB dyslipoproteinemias will be briefly outlined. Our objective is to provide a physiological framework for health care givers to understand why apoB is a more accurate marker of cardiovascular risk than LDL-C or non-high-density lipoprotein cholesterol.
2019 年,欧洲心脏病学会/欧洲动脉粥样硬化学会指出,载脂蛋白 B(apoB)是心血管风险的更准确标志物,优于低密度脂蛋白胆固醇(LDL-C)和非高密度脂蛋白胆固醇。此后,支持 apoB 的证据不断增加。这篇综述阐述了 apoB 作为载脂蛋白 B 致动脉粥样硬化脂蛋白颗粒乳糜微粒残粒、极低密度脂蛋白和低密度脂蛋白颗粒所致心血管风险标志物具有优越性的生理机制。首先,将概述这些不同 apoB 颗粒的性质和相对数量。这将清楚地表明为什么低密度脂蛋白颗粒几乎总是心血管风险的主要决定因素,以及为什么甘油三酯和 LDL-C 的浓度可能掩盖这种关系。接下来,将概述控制极低密度脂蛋白和低密度脂蛋白颗粒数量的机制,因为除了脂蛋白脂酶缺乏症外,apoB 颗粒的总数决定了心血管风险。然后,将回顾控制极低密度脂蛋白和低密度脂蛋白颗粒内胆固醇质量的机制,因为这些机制导致了 apoB 颗粒内胆固醇质量(如 LDL-C 或非高密度脂蛋白胆固醇所测量)与 apoB 所测量的 apoB 颗粒数量之间的不相符,从而创造了 apoB 优于 LDL-C 和非高密度脂蛋白胆固醇的预测能力。最后,将简要概述主要的 apoB 血脂异常症。我们的目的是为医疗保健提供者提供一个生理框架,以了解为什么 apoB 是比 LDL-C 或非高密度脂蛋白胆固醇更准确的心血管风险标志物。